U.S. markets open in 24 minutes
  • S&P Futures

    3,780.25
    -9.25 (-0.24%)
     
  • Dow Futures

    30,694.00
    -87.00 (-0.28%)
     
  • Nasdaq Futures

    11,490.75
    -38.75 (-0.34%)
     
  • Russell 2000 Futures

    1,702.80
    -5.20 (-0.30%)
     
  • Crude Oil

    108.61
    +2.85 (+2.69%)
     
  • Gold

    1,788.00
    -19.30 (-1.07%)
     
  • Silver

    19.40
    -0.95 (-4.68%)
     
  • EUR/USD

    1.0413
    -0.0070 (-0.67%)
     
  • 10-Yr Bond

    2.9060
    -0.0660 (-2.22%)
     
  • Vix

    28.54
    +0.38 (+1.35%)
     
  • GBP/USD

    1.2013
    -0.0162 (-1.33%)
     
  • USD/JPY

    135.2120
    -0.5160 (-0.38%)
     
  • BTC-USD

    19,292.30
    +79.01 (+0.41%)
     
  • CMC Crypto 200

    414.89
    -16.58 (-3.84%)
     
  • FTSE 100

    7,162.10
    -7.18 (-0.10%)
     
  • Nikkei 225

    25,935.62
    -457.42 (-1.73%)
     

New Study Shows Open-Source Automated Insulin Delivery is a Safe and Effective Treatment Option for People with Type 1 Diabetes

·5 min read

First-of-Its-Kind Study Compares Open-Source Automated Insulin Delivery to Sensor-Augmented Pump Therapy

NEW ORLEANS, June 6, 2022 /PRNewswire/ -- Results from the CREATE Trial demonstrated open-source automated insulin delivery (AID) systems are a safe and effective therapy for people with type 1 diabetes. Findings from the randomized controlled trial (RCT) comparing open-source AID to sensor-augmented pump therapy (SAPT) were presented today at the 82nd Scientific Sessions of the American Diabetes Association® (ADA).

New Study Shows Open-Source Automated Insulin Delivery is a Safe and Effective Treatment Option for People with Type 1 Diabetes
New Study Shows Open-Source Automated Insulin Delivery is a Safe and Effective Treatment Option for People with Type 1 Diabetes

Open-source AID systems were developed to reduce the burden of living with diabetes by combining an insulin pump, continuous glucose monitor (CGM), and an algorithm that automatically adjusts insulin delivery every five minutes to keep glucose levels in target range. The technology was developed by people with diabetes and shared openly, commonly referred to as open-source, so that others could evaluate the system and choose to use it themselves. These open-source systems were available for years before commercial AID systems and are used by people with type 1 diabetes worldwide.

The CREATE Trial is the first randomized controlled trial to evaluate the safety and efficacy of the most commonly used open-source AID system. The study compared open-source AID, using the OpenAPS algorithm from a version of AndroidAPS implemented in a smartphone with the DANA-i insulin pump and Dexcom G6® CGM, to SAPT. A diverse population of patients, many of whom had little or no experience with AID, were recruited to a 24-week, multi-center RCT, which included children (7–15 years) and adults (16–70 years), to examine efficacy and safety of open-source AID.

Results of the trial included:

  • The primary outcome was the percent of time in target sensor glucose range (TIR; 3.9-10 mmol/L [70-180 mg/dL]) between open-source AID and SAPT during the last two weeks of the RCT.

  • Both children and adults achieved more time in range (TIR), when using the open-source AID system compared to treatment without automation (SAPT).

"We were encouraged to see the greatest improvements in time in range were in those who had the lowest time in range at the start of the study. This supports the finding that a wide range of people with diabetes who want to use this technology could benefit from it, regardless of their outcomes with previous therapies," said Dana Lewis, diabetes researcher, a founder of the open-source artificial pancreas movement, OpenAPS, and study investigator.

"While open source AID is not yet approved by the FDA, we know people worldwide are using it to manage their diabetes. Our findings demonstrate that this is a safe and effective technology and adds to the body of evidence supporting use of open-source AID for improving glycemic outcomes," commented Dr. Martin de Bock, pediatric endocrinologist at the University of Otago, Christchurch, New Zealand, and lead investigator of the study.

The authors hope these findings provide both people with diabetes and clinicians with additional information to use when evaluating open-source AID options for people living with diabetes.

Research presentation details:

Dr. de Bock, in conjunction with study investigators, presented the findings of the trial during the oral presentation listed below:

For more information, please contact the ADA Scientific Sessions media team onsite at the Ernest N. Morial Convention Center from June 3–7 by phone at 504-670-4902, or by email at SciSessionsPress@diabetes.org.

About the ADA's Scientific Sessions
The ADA's 82nd Scientific Sessions, the world's largest scientific meeting focused on diabetes research, prevention, and care, will be a hybrid event held June 3–7, 2022 at the Ernest N. Morial Convention Center in New Orleans, LA. Leading physicians, scientists, and health care professionals from around the world will unveil cutting-edge research, treatment recommendations, and advances toward a cure for diabetes. We are eager to get back to safely participating in person and networking with colleagues while hearing the latest scientific advances and groundbreaking research presentations. Learn more and register at scientificsessions.diabetes.org and join the Scientific Sessions conversation on social media using #ADA2022.

About the American Diabetes Association
The American Diabetes Association (ADA) is the nation's leading voluntary health organization fighting to bend the curve on the diabetes epidemic and help people living with diabetes thrive. For 81 years, the ADA has driven discovery and research to treat, manage, and prevent diabetes while working relentlessly for a cure. Through advocacy, program development, and education we aim to improve the quality of life for the over 133 million Americans living with diabetes or prediabetes. Diabetes has brought us together.What we do next will make us Connected for Life. To learn more or to get involved, visit us at diabetes.org or call 1-800-DIABETES (1-800-342-2383). Join the fight with us on Facebook (American Diabetes Association), Spanish Facebook (Asociación Americana de la Diabetes), LinkedIn (American Diabetes Association), Twitter (@AmDiabetesAssn), and Instagram (@AmDiabetesAssn).

Contact: Daisy Diaz, 504-670-4902
SciSessionsPress@diabetes.org

 

(PRNewsFoto/American Diabetes Association)
(PRNewsFoto/American Diabetes Association)
Cision
Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/new-study-shows-open-source-automated-insulin-delivery-is-a-safe-and-effective-treatment-option-for-people-with-type-1-diabetes-301561602.html

SOURCE American Diabetes Association